AMRX Stock Analysis: Buy, Sell, or Hold?
AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock
$17.18
0.17 (1.00%)
▲
5d:
+1.54%
30d:
+12.14%
90d:
+37.0%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 04, 2026
20d
Get Alerted When AMRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: AMRX shows positive signals but monitor for confirmation. Market pricing in 6.2% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: AMRX shows positive signals but monitor for confirmation. Market pricing in 6.2% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$21.97
Based on 8.9% avg growth
INTRINSIC VALUE TODAY
$13.64
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AMRX is currently trading at $17.18, which is considered slightly high relative to its 30-day fair value range of $15.16 to $17.45. From a valuation perspective, the stock is trading at a premium (Forward PE: 15.3) compared to its historical average (12.8). At these levels, the market is pricing in 6.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AMRX is in a strong uptrend. The price is approaching resistance at $17.49. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AMRX is in a strong uptrend. The price is approaching resistance at $17.49. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$15.16 -
$17.45
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
60.5%
Protect Your Profits
AMRX is technically overbought (RSI 71). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($17.25)
- NEUTRAL: PE elevated vs history but 6.2% growth expectation is conservative given 385% recent growth
Trading Range Analysis
30-Day Trading Range
$15.16 -
$17.45
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$16.45
Resistance Level
$17.49
Current Trend
Strong Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.29
Wall Street Target
$17.25
(+0.4%)
Revenue Growth (YoY)
3.9%
Earnings Growth (YoY)
384.6%
Profit Margin
4.0%
Valuation Premium vs History
+6.2% premium
PE vs Historical
15.3 vs 12.8
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+6.2%
(market-implied from PE analysis)
1-Year Target
$18.25
(+6%)
2-Year Target
$19.38
(+13%)
3-Year Target
$20.58
(+20%)
3-Yr Target (if PE normalizes)
(PE: 15→13)
PE COMPRESSION
$17.22
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 13.8%)
$36.05
(+110%)
Base:
(SPY PE: 15.3, Growth: 13.8%)
$25.32
(+47%)
Bear:
(PE: 12.8, Growth: 13.8%)
$21.19
(+23%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (46x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 45.97 | Current EPS (TTM): $0.37
Bull Case
$37.42
(+118%)
Analyst growth 100.0%, PE expands to 50.6
Base Case
$34.02
(+98%)
Market implied 100.0%, PE stable at 46.0
Bear Case
$11.57
(-33%)
Severe decline -20.0%, PE contracts to 39.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 13, 2026 10:33 PM ET
Data refreshes hourly during market hours. Next update: 11:33 PM
Data refreshes hourly during market hours. Next update: 11:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AMRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 51 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 55 HOLD |
Advanced AMRX Option Strategies
Professional options setups generated by AI based on today's AMRX price and gamma walls.
